

COVID-19 and diabetes: Knowledge in progress -Akhtar Hussain -Faculty of Health Sciences, Nord University, Norway

Akhtar Hussain

Abstract

We aimed to briefly review the general characteristics of the novel coronavirus (SARS-CoV-2) and provide a better understanding of the coronavirus disease (COVID-19) in people with diabetes, and its management. **Methods:** We searched for articles in PubMed and Google Scholar databases till 02 April 2020, with the following keywords: "SARS-CoV-2", "COVID-19", "infection", "pathogenesis", "incubation period", "transmission", "clinical features", "diagnosis", "treatment", "diabetes", with interposition of the Boolean operator "AND". **Results:** The clinical spectrum of COVID-19 is heterogeneous, ranging from mild flu-like symptoms to acute respiratory distress syndrome, multiple organ failure and death. Older age, diabetes and other comorbidities are reported as significant predictors of morbidity and mortality. Chronic inflammation, increased coagulation activity, immune response impairment, and potential direct pancreatic damage by SARS-CoV-2 might be among the underlying mechanisms of the association between diabetes and COVID-19. No conclusive evidence exists to support the discontinuation of angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers or thiazolidinediones because of COVID-19 in people with diabetes. Caution should be taken to potential hypoglycemic events with the use of chloroquine in these subjects. Patient tailored therapeutic strategies, rigorous glucose monitoring and careful consideration

of drug interactions might reduce adverse outcomes. We conducted a scoping review to provide a brief summary of the general characteristics of COVID-19, as well as a more detailed description and critical assessment of the association between this new infectious disease and diabetes. We hope this review can provide meaningful information for future research and ultimately contribute to better clinical management of patients with COVID-19 and diabetes. Most initial COVID-19 patients had a direct contact history with a local Chinese seafood and wildlife market, suggesting a common-source zoonotic exposure as the main mode of transmission [10]. Findings from virus genome sequencing analysis have pointed out that SARS-CoV-2 and bat coronavirus (bat CoV) might share the same ancestor, although bats are not for sale in this seafood market [11]. Later cases were reported among health care workers and others without exposure history of wildlife or visiting Wuhan, which indicated human-to-human transmission [10]. Currently, it is considered that the virus can be mainly transmitted through droplets, direct contact and aerosols. Droplets transmission may occur when respiratory droplets, produced when an infected person coughs or sneezes, are ingested or inhaled by individuals nearby (within about 6 feet). A subject can also get infected by touching a surface or object contaminated with the virus and subsequently touching his/her mouth, nose, or eyes [12]. Additionally, it has been shown experimentally that the virus can remain viable in aerosols for at least 3h [13], and can be

Akhtar Hussain

Nord University, Norway, E-mail: hussain.akhtar@nord.no

transmitted in closed environments if inhaled into the lungs[12]. Therefore, airborne transmission is a possibility during aerosol generating procedures, e.g., endotracheal intubation, bronchoscopy, non-invasive positive-pressure ventilation, tracheostomy, cardiopulmonary resuscitation, etc[14]. Although viable virus has been identified in fecal swabs, the fecal-oral route does not appear to be a driver of COVID-19 transmission. The diagnosis of COVID-19 cannot be made without microbiologic analysis. Patients who meet the criteria discussed below should undergo testing for SARS-CoV-2, in addition to testing for other respiratory pathogens (e.g., influenza, respiratory syncytial virus, etc). Since testing for COVID-19 in suspected cases is limited owing to inadequate capacity, local health authorities may introduce specific criteria for priority cases[23]. Although many laboratory tests have been developed, real-time fluorescence (RT-PCR) has been the current standard diagnostic method for diagnosis of COVID-19, by detecting the positive nucleic acid of SARS-CoV-2 in sputum, throat swabs, and secretions of the lower respiratory tract samples

Although the pathophysiological mechanisms are still not understood, it has been observed that most severe and fatal cases with COVID-19 have occurred in the elderly or in patients with underlying comorbidities, particularly CVDs, diabetes mellitus, chronic lung and renal disease, hypertension, and cancer[7,20,26,27]. One Chinese meta-analysis including 1527 patients showed that the most prevalent cardiovascular metabolic comorbidities with COVID-19 were hypertension (17.1%, 95%CI 9.9–24.4%) and cardio-cerebrovascular disease (16.4%, 95%CI 6.6–26.1%), followed by diabetes (9.7%, 95% CI 6.9–12.5%). In this report, patients with diabetes or hypertension had a 2-fold increase in risk of severe disease or requiring intensive care unit (ICU) admission, while those with cardio-cerebrovascular disease had a 3-fold increase[28]. In a sub-set of 355 patients with COVID-19 in Italy who died, the

mean number of pre-existing underlying conditions was 2.7, and only 3 subjects did not have any comorbidity

Conclusions: Suggestions are made on the possible pathophysiological mechanisms of the relationship between diabetes and COVID-19, and its management. No definite conclusions can be made based on current limited evidence. Further research regarding this relationship and its clinical management is warranted.

COVID-19 has rapidly spread since its initial identification in Wuhan and has shown a broad spectrum of severity. Early isolation, early diagnosis, and early management might collectively contribute to a better control of the disease and outcome. Diabetes and other comorbidities are significant predictors of morbidity and mortality in patients with COVID-19. Future research is urgently needed to provide a better understanding regarding potential differences in genetic predispositions across populations, underlying patho-physiological mechanisms of the association between COVID-19 and diabetes, and its clinical management.

This work is partly presented at 52th Annual Congress on Neuroscience and stroke 2020, December 14, 2020

Akhtar Hussain

Nord University, Norway, E-mail: hussain.akhtar@nord.no